Organogenesis (ORGO) announced the initiation of a rolling submission of a Biologics License Application to the FDA for ReNu, a cryopreserved, amniotic suspension allograft developed for the management of symptomatic knee arthritis. Organogenesis plans to complete the BLA submission with the final modules submitted in the first half of 2026.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ORGO:
- Organogenesis Nears Key Data Milestone With Phase 3 Knee Osteoarthritis Study
- Morning Movers: Vital Farms dips after cutting FY25 revenue view
- Buy Rating for Organogenesis Holdings: FDA Progress and Favorable Policy Changes Drive Optimism
- Organogenesis plans to file BLA for ReNu before end of December
- Organogenesis price target raised to $9 from $7 at BTIG